Fresolimumab
- Generic Name
- Fresolimumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 948564-73-6
- Unique Ingredient Identifier
- 375142VBIA
- Background
Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
- Associated Conditions
- -
- Associated Therapies
- -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT03064074
- Locations
- ๐บ๐ธ
Baylor College of Medicine, Houston, Texas, United States
๐บ๐ธOregon Health Science University, Portland, Oregon, United States
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
- Conditions
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 36
- Registration Number
- NCT01665391
- Locations
- ๐บ๐ธ
Investigational Site Number 4009, San Francisco, California, United States
๐บ๐ธInvestigational Site Number 4004, Baltimore, Maryland, United States
๐บ๐ธInvestigational Site Number 4005, Atlanta, Georgia, United States
Safety and Imaging Study of GC1008 in Glioma
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 12
- Registration Number
- NCT01472731
- Locations
- ๐ณ๐ฑ
University Medical Center Groningen, Groningen, Netherlands
Fresolimumab and Radiotherapy in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 23
- Registration Number
- NCT01401062
- Locations
- ๐บ๐ธ
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
๐บ๐ธNew York University Langone Medical Center Cancer Center, New York, New York, United States
Fresolimumab In Systemic Sclerosis
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boston University
- Target Recruit Count
- 18
- Registration Number
- NCT01284322
- Locations
- ๐บ๐ธ
Boston University School of Medicine; Rheumatology/Arthritis Center, Boston, Massachusetts, United States
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT01112293
- Locations
- ๐บ๐ธ
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.